12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
ContraFect (NASDAQ:CFRX) stock moved upwards by 4.9% to $2.76 during Friday's after-market session. The company's market cap stands at $108.5 million.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
ContraFect (NASDAQ:CFRX) stock increased by 4.9% to $2.76 during Thursday's after-market session. The company's market cap stands at $108.5 million.
ContraFect Announces Award From Cystic Fibrosis Foundation To Evaluate Exebacase As A Potential Treatment For Serious MRSA Lung Infections Associated With Cystic Fibrosis
ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical
From Benzinga’s Global Small Cap Conference: ContraFect President & CEO, Roger J. Pomerantz, M.D., F.A.C.P. Begins Presenting
https://www.youtube.com/watch?v=XkOilNZqoEI
CFRX: Direct Lytic Agents Show In Vitro Activity Against Gram-Negative Pathogens…
By David Bautz, PhD
NASDAQ:CFRX
READ THE FULL CFRX RESEARCH REPORT
ContraFect Shares Move Higher On Spike In Volume, Co. Receives Notice Of Allowance For U.S. Patent Application Titled ‘ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION, AND COMPOSITIONS, COMBINATIONS AND METHODS FOR USE THEREOF’
https://patentcenter.uspto.gov/#!/applications/16674149/ifw/docs
CFRX: New Data on Exebacase Shows Rapid Resolution of Symptoms in Phase 2 Trial…
By David Bautz, PhD
NASDAQ:CFRX
READ THE FULL CFRX RESEARCH REPORT